Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
H. Lee Moffitt Cancer Center and Research Institute
Wake Forest University Health Sciences
Mayo Clinic
University of Kentucky
BeiGene
University Health Network, Toronto
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Fundación GECP
Checkpoint Therapeutics, Inc.
EpicentRx, Inc.
Novartis
Hoosier Cancer Research Network
Samsung Bioepis Co., Ltd.
NantCell, Inc.
Humanetics Corporation
Canadian Cancer Trials Group
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
Wake Forest University Health Sciences
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Fox Chase Cancer Center
University of Pittsburgh
SCRI Development Innovations, LLC
Eli Lilly and Company
Duke University
Massachusetts General Hospital
Mereo BioPharma
Celgene
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Eli Lilly and Company
Bristol-Myers Squibb
Incyte Corporation
Northwestern University
M.D. Anderson Cancer Center